Aurigene Oncology reports successful Phase 1 trial for DRL-1801 CAR-T cell therapy in India, showing high response rate and no severe side effects, leading to Phase 2 trial approval.

Aurigene Oncology, a subsidiary of Dr. Reddy's Laboratories, reported successful Phase 1 trial results for Ribrecabtagene autoleucel (DRL-1801), a BCMA-directed CAR-T cell therapy for relapsed/refractory multiple myeloma in India. All eight patients showed clinical response, with 62.5% achieving stringent complete response, and no severe side effects noted. The Drugs Controller General of India has approved the Phase 2 trial following these positive results.

October 07, 2024
10 Articles

Further Reading